EMA Authorised: Calquence (acalabrutinib;acalabrutinib maleate) — AstraZeneca AB

View source ↗

Summary

EMA authorised Calquence (acalabrutinib) for use in chronic lymphocytic leukemia and small lymphocytic lymphoma; the product is manufactured by AstraZeneca AB.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)

Snippet

Status: Authorised. Therapeutic area: Leukemia, Lymphocytic, Chronic, B-Cell. MAH: AstraZeneca AB. Decision date: 28/08/2025